Study guide
24.1 Essential Records and Site/Sponsor Reconciliation
ACRP CCRA Certified Clinical Research Associate Study Guide 2026 Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Format, Eligibility and Registration
1.1 Exam Format, Eligibility and Current References 1.2 Registration, Fees and Candidate Decisions
2 Chapter 2: CRA Responsibilities and Study Planning
2.1 The CRA Role, Data Integrity and Product Oversight 2.2 Official Blueprint and Study Strategy
3 Chapter 3: Protocols, Endpoints and Trial Design
3.1 Protocol Elements and Endpoint Hierarchy 3.2 Endpoint Interpretation and Eligibility Rationale 3.3 Eligibility Verification and Trial Designs
4 Chapter 4: Bias Control, Blinding and Product Information
4.1 Bias, Randomisation and Comparator Controls 4.2 Unblinding and Investigator Brochure Content 4.3 Reference Safety Information and IB Updates
5 Chapter 5: Estimands and Device Instructions
5.1 Estimands and Intercurrent Events 5.2 Device Instructions, Configuration and Training
6 Chapter 6: Ethical Foundations and Independent Oversight
6.1 Ethical Foundations and the 2024 Declaration of Helsinki 6.2 Vulnerability, Voluntariness and Compensation 6.3 IRB/IEC Composition and Independent Review
7 Chapter 7: Ethics Communication and Informed Consent
7.1 Ethics Reporting, Approval Status and Version Control 7.2 Informed Consent Information and Meaningful Choice 7.3 Consent Documentation, Special Circumstances and Updates
8 Chapter 8: Recruitment, Retention and Confidentiality
8.1 Ethical Eligibility, Recruitment and Retention 8.2 Privacy, Confidentiality and Appropriate Access
9 Chapter 9: Safety Definitions and Classification
9.1 Adverse Event Definitions and Actual Life-Threatening Risk 9.2 Seriousness, Severity and Medical Importance 9.3 Causality, Expectedness and Reference Safety Information
10 Chapter 10: Safety Detection, Reporting and Oversight
10.1 Detecting Events, AESIs and Collection Windows 10.2 Expedited Reporting and the Sponsor Awareness Clock 10.3 Immediate Site Reporting and Independent Safety Oversight
11 Chapter 11: Follow-Up, Adherence and Conflicts
11.1 Safety Communications, Reconciliation and Follow-Up 11.2 Adherence, Discontinuation and Participant Choice 11.3 Conflicts of Interest and Prorated Payments
12 Chapter 12: Development Stages and Product Management
12.1 Nonclinical Background and Human Pharmacology 12.2 Exploratory, Confirmatory and Therapeutic-Use Studies 12.3 Product Storage, Labelling and Excursion Response
13 Chapter 13: Accountability, Integrity and Regulatory Status
13.1 Product Accountability and Adherence Calculations 13.2 Potential Fraud, Misconduct and Evidence Preservation 13.3 Submissions, Authorisation Status and Trial Reporting
14 Chapter 14: Current GCP Principles and Delegation
14.1 The Eleven Current GCP Principles 14.2 Proportionality and Investigator Oversight 14.3 Delegation, Qualifications and Task Authority
15 Chapter 15: Oversight, Protocol Control and Amendments
15.1 Clinical Oversight and Immediate-Hazard Changes 15.2 Deviation Classification and Resolution
16 Chapter 16: Implementation and Trial Responsibilities
16.1 Amendment Implementation and Communication 16.2 Sponsor, Investigator and Service-Provider Roles
17 Chapter 17: Quality Planning, Root Causes and CAPA
17.1 Quality Planning and Risk Management 17.2 Root Cause Analysis and CAPA Design 17.3 CAPA Implementation and Effectiveness Verification
18 Chapter 18: Risk Assessment and Monitoring Methods
18.1 Risk Assessment and Centralised Surveillance 18.2 Monitoring Methods and Source Review
19 Chapter 19: Quality Metrics, Plans and Communication
19.1 KRIs, Acceptable Ranges and Trial-Level Quality 19.2 Monitoring Plans, Co-Monitoring and Communication
20 Chapter 20: Site Qualification and Readiness
20.1 Site Qualification and Investigator Capacity 20.2 Recruitment Feasibility and Evidence-Based Site Selection 20.3 Site Readiness and Activity-Specific Release
21 Chapter 21: Initiation, Equipment and Supplies
21.1 Initiation Training and Readiness Walkthroughs 21.2 Equipment, Maintenance and Study Supplies
22 Chapter 22: Samples, Diagnostics and Financial Feasibility
22.1 Specimens, Diagnostic Results and Rater Quality 22.2 Contracts, Budgets and Operational Feasibility
23 Chapter 23: Interim Monitoring and Reporting
23.1 Interim Visit Preparation and Consent Review 23.2 Monitoring Eligibility, Safety and Products 23.3 Investigator Debrief and Monitoring Reports
24 Chapter 24: Essential Records, Audits and Findings
24.1 Essential Records and Site/Sponsor Reconciliation 24.2 Version History, Resolution Evidence and Noncompliance 24.3 Audits, Inspections and Closure Planning
25 Chapter 25: Close-Out, Retention and Destruction
25.1 Close-Out, Archiving and Continuing Obligations 25.2 Retention, Destruction and Long-Term Access
26 Chapter 26: Source Records and Good Documentation
26.1 Source Records and Foundational ALCOA Principles 26.2 Good Documentation, Completeness and Corrections 26.3 Source Access, Certified Copies and Context
27 Chapter 27: Electronic Systems, Metadata and Queries
27.1 EDC Design and Fit-for-Purpose Systems 27.2 Audit Trails, Electronic Outcomes and Device Choice 27.3 Queries, Coding and Supported Clinical Meaning
28 Chapter 28: Dataset Finalisation and Critical Data
28.1 Safety Reconciliation and Dataset Finalisation 28.2 Critical Data, Acquisition Tools and Interim Findings
24.1 Essential Records and Site/Sponsor Reconciliation
Key Takeaways Explain This Topic AI
E6(R3) Appendix C supports evaluation of conduct, compliance and reliable results.
Original records generally remain with the responsible generating party.
TMF and ISF need appropriate relevant records rather than identical copies of everything.
Last updated: October 2026
Essential Records and Site/Sponsor Reconciliation
E6(R3) Appendix C treats essential records as evidence supporting evaluation of trial conduct, GCP compliance and result reliability. Some generally precede trial start; others arise during conduct or closure. The record's nature and relevance determine essentiality, not its presence in a universal folder checklist.
Stage Examples What the record demonstrates
Before affected activities Approved protocol/consent, authorisations, agreements, qualifications and suitable systems The study was ready and permitted to proceed
During conduct Consent, safety reports, source records, monitoring, changes and product accountability What actually happened and how important issues were managed
At completion/termination Final reports, product disposition, dataset finalisation and archive arrangements Responsible closure and continuing availability of evidence
Original records generally remain with the responsible party that generated them. Some records are sponsor-only, some site-only, and some are relevant to both. A sponsor monitoring report and a site follow-up communication are different records; the sponsor report is not automatically required in the ISF. The site should receive the information it needs to address findings and retain its own relevant records.
The records can be held in different repositories if their locations and access are clear. A protocol-independent validation record or institutional procedure need not be duplicated into every trial folder when it is appropriately referenced and retained. The aim is reconstruction and accountability rather than the largest possible binder.
Trial Master File (TMF) vs. Investigator Site File (ISF)
A critical distinction in clinical research management is the relationship between the sponsor's master repository and the site's local repository:
The Trial Master File (TMF)
The Trial Master File is the sponsor's comprehensive, overarching collection of essential documents for an entire clinical trial. Maintained either directly by the sponsor or delegated to a Contract Research Organization (CRO), the TMF houses trial-level governance documents, health authority submissions, central laboratory records, safety oversight committee minutes, data management specifications, and site-level records across all participating global trial centers. Under modern GCP, the TMF must be maintained in a continuous state of inspection readiness.
The Investigator Site File (ISF)
The Investigator Site File —frequently referred to in the United States as the Regulatory Binder —is maintained directly by the Principal Investigator and site study team at the clinical trial site. The ISF contains all essential documents specific to that particular investigative site's authorization, staffing, patient cohort, and operational execution.
The Confidentiality Boundary & Repository Segregation
The sponsor and investigator retain relevant records for their respective responsibilities, sharing appropriate evidence such as approvals and follow-up communication. They do not need identical repositories. Participant-identifying records need appropriate confidentiality controls and generally remain with the investigator/institution.
Reconciling site and sponsor records
A useful reconciliation compares what should exist, where it belongs, its version/status and whether the responsible party can retrieve it. Sample an approval chain: amendment text, submission, decision, implementation date, staff information/training and affected consent materials. A present approval letter alone does not establish that the authorised version reached practice.
- Check Example question Appropriate follow-up
- Identity Does the document belong to this trial and site? Correct misfiling through a traceable process
- Version Does the decision cover the document used? Reconstruct the approval/implementation sequence
Completeness Are attachments, signatures and relevant metadata present? Retrieve missing evidence; do not backdate
Ownership Should the record be held by sponsor, investigator or both? Preserve the responsible party's record and access
Accessibility Can the retained record be read and retrieved? Resolve permissions, indexing or format risks
Confidentiality/blinding Is the recipient authorised to see its content? Restrict access and invoke incident procedures if needed
If identifiable participant information was uploaded incorrectly, promptly restrict inappropriate access and notify the designated privacy/security and quality functions. Preserve evidence and follow a controlled correction/removal process, including any required audit record. Do not independently purge the file or audit trail. E6(R3) allows rare justified audit-trail corrections, for example accidental personal information, only with a log of the action and justification.
Filing systems and reference models can be useful, but a commercial model's zone numbers are not ICH requirements or CCRA references. Apply the actual sponsor index while understanding the function and confidentiality of each record. Do not place unblinded material in a broadly accessible folder merely because its file label appears to fit.
Record identity and record status
A file can have the right title but the wrong status. An unsigned draft agreement, a submitted consent revision and an approved final version may all share a trial number while proving different things. Review version, approval state, relevant dates and scope together. A duplicate uploaded under a new filename does not create a new decision. Preserve the authoritative record and traceable changes while correcting indexing or filing errors through the controlled process. Reconciliation should establish what evidence supports the activity at the time, rather than merely counting documents with familiar names.
Official sources
Checked October 18, 2026: ICH E6(R3), Principles and Annex 1 .